184 related articles for article (PubMed ID: 8690449)
21. The CD52 antigen and development of the CAMPATH antibodies.
Hale G
Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
[No Abstract] [Full Text] [Related]
22. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
23. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
24. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
25. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
27. A personal history of the CAMPATH-1H antibody.
Waldmann H
Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
[TBL] [Abstract][Full Text] [Related]
28. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
29. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
30. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.
Lifely MR; Hale C; Boyce S; Keen MJ; Phillips J
Glycobiology; 1995 Dec; 5(8):813-22. PubMed ID: 8720080
[TBL] [Abstract][Full Text] [Related]
31. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.
Crowe JS; Hall VS; Smith MA; Cooper HJ; Tite JP
Clin Exp Immunol; 1992 Jan; 87(1):105-10. PubMed ID: 1339322
[TBL] [Abstract][Full Text] [Related]
32. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.
Hertenstein B; Wagner B; Bunjes D; Duncker C; Raghavachar A; Arnold R; Heimpel H; Schrezenmeier H
Blood; 1995 Aug; 86(4):1487-92. PubMed ID: 7632956
[TBL] [Abstract][Full Text] [Related]
33. [Preparation and identification of mouse anti-human CD52 functional antibody].
Liu Y; Qu H; Shi L; Huang L; Zhang Y; Zhu W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):56-9, 64. PubMed ID: 23294718
[TBL] [Abstract][Full Text] [Related]
34. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Cheetham GM; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1998 Nov; 284(1):85-99. PubMed ID: 9811544
[TBL] [Abstract][Full Text] [Related]
35. Campath-1H treatment of multiple sclerosis.
Jones JL; Coles AJ
Neurodegener Dis; 2008; 5(1):27-31. PubMed ID: 18075272
[TBL] [Abstract][Full Text] [Related]
36. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
37. CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.
Oko A; Wyrwicz LS; Glyda M; Idasiak-Piechocka I; BiĆczak-Kuleta A; Kaczmarczyk M; Drozd A; Ciechanowicz A; Czekalski S
Ann Acad Med Stetin; 2009; 55(2):22-6. PubMed ID: 20349607
[TBL] [Abstract][Full Text] [Related]
38. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
39. Epitope analysis of immunoglobulins against gp20, a GPI-anchored protein of the human sperm surface homologous to leukocyte antigen CD52.
Flori F; Giovampaola CD; Focarelli R; Secciani F; La Sala GB; Nicoli A; Hale G; Rosati F
Tissue Antigens; 2005 Sep; 66(3):209-16. PubMed ID: 16101832
[TBL] [Abstract][Full Text] [Related]
40. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein.
Hale G
Immunotechnology; 1995 Dec; 1(3-4):175-87. PubMed ID: 9373346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]